C. Moore

High-dose dienogest (20 mg/day) was used for the treatment of endometriosis in women aged 18-52 years after laparoscopic and histological diagnosis of endometriosis and staging according to the revised American Fertility Society criteria. T…

AIM OF THE STUDY: Influence of two hormonal therapies (GnRH agonist--leuprolein acetate and a new progestin--dienogest) on symptoms of endometriosis in patients with different clinical grade of disease. MATERIAL AND METHODS: 34 women with e…

The effects of two oral contraceptive combinations, dienogest 2.0 mg plus ethinyl estradiol 0.03 mg (Valette) and desogestrel 0.15 mg plus ethinyl estradiol 0.02 mg (Lovelle), on the human immune system were compared over one treatment cycl…

Studies have been undertaken to investigate the modulatory effects of a combination of 30 μg ethinylestradiol and 2.00 mg dienogest (Valette®) on ovarian function and on the hemostatic system. Modulation of ovarian function was investigated…

Dienogest is the first non-alkylated 19-norprogestin on the market. This so-called hybrid progestin combines the typical qualities of the modern 19-norprogestins with those of natural progesterone and synthetic hydroxyprogesterone derivativ…

Antiandrogens or progestins with an antiandrogenic component usually have only a weak antigonadotropic activity. It is thus possible that the antiandrogenic effect on the cellular level is cancelled or at least reduced by an increased ovari…

Vergleichende Untersuchungen zum Einfluß von Ethinylestradiol-haltigen Kontrazeptiva mit Dienogest- oder Levonorgestrel-Komponente auf die Cytochrom P-450-Funktion in vivo was published in Dienogest on page 149.

Vergleichende Untersuchungen zum Einfluß von Ethinylestradiol-haltigen Kontrazeptiva mit Dienogest- oder Levonorgestrel-Komponente auf die Cytochrom P-450-Funktion in vivo was published in Dienogest on page 149.